Just found information on an upcoming symposium on the topic:
EVIDENCE BASED USE OF T3 + T4 COMBINATIONS
Endocrinologists are frequently asked to consult on patients taking L-thyroxine (T4) but appear dissatisfied with their therapy. However, the use of combination therapy with liothyronine (T3) remains highly controversial with conflicting results from clinical trials. Recent scientific studies have provided new insight into the complex relationship between serum and tissue thyroid hormone levels justifying a review of the evidence base for the use of T4+T3 combinations and the design of future clinical trials in this area.
This innovative symposium will occur simultaneously on Sunday 3rd November 2019 in Chicago, US and London, UK, representing a collaborative effort between the ATA, BTA and ETA, to bring together leading experts in this area from North America and Europe. It will be a live meeting in both locations, with the UK audience accessing a webcast to view the US presentations and the US audience accessing a webcast to view the UK presentations with the opportunity for both audiences to ask questions to all speakers.
The symposium will conclude with fully interactive workshops on the use of combination therapy in the UK, and a patient discussion forum in the US. Co-chaired by U.S. based Jaqueline Jonklaas, MD and U.K. based Colin M. Dayan, MA, FRCP, PhD, the anticipated goal is to use the symposium content and discussion as material to produce a consensus statement about the design of future combination therapy trials and to assist endocrinologists in advising their patients on the current evidence base behind combination therapy.
None of us are invited and the whole business is to keep the debate within the little cabal of "experts" who have up till now dragged their feet over T3/T4 therapy. It is they, after all, who must "lead the field" in seeing the light, and not erks from the margins like ourselves. That would never do would it? Sorry, sarcasm has boiled over.